[9] [10] Several factors may explain why some individuals experience fatigue whilst taking GLP-1 medications: Reduced caloric intake : The appetite-suppressing effects can lead to significantly lower food consumption, potentially resulting in inadequate energy intake, particularly if patients are not consuming balanced, nutrient-dense meals
Accordingly, supplementing OEA to obese mice reverses this state of dorsal striatal dopamine deficit in a vagal-afferentdependent manner [104]
We established that this is likely a consequence of GLP-1RA treatment, rather than a general change associated with weight loss, because it was not evident with other agents (amylin) yielding similar weight loss and did not occur in the weight-matched group
Colonna, M., & Butovsky, O
The authors also noted the critical limitation: no human data exists to confirm whether these effects translate to clinical outcomes in people
Side-by-Side Comparison of Nausea Management Methods The effectiveness of each approach can vary depending on how its implemented and individual responses